Market Overview

bluebird bio to Present at Investor Conferences in September


bluebird bio, Inc. (NASDAQ:BLUE) today announced that members of the
management team will present at the following upcoming investor

  • Citi 13th Annual Biotech Conference, Wednesday, September
    5, 10:30 a.m. ET at the Four Seasons Boston, Boston, MA
  • Wells Fargo Securities 2018 Healthcare Conference, Thursday, September
    6, 10:55 a.m. ET at the Westin Copley Place, Boston, MA
  • Morgan Stanley 16th Annual Global Healthcare Conference,
    Thursday, September 13, 12:20 p.m. ET at the Grand Hyatt, New York City

To access the live webcasts of bluebird bio's presentations, please
visit the "Events & Presentations" page within the Investors and Media
section of the bluebird bio website at
Replays of the webcasts will be available on the bluebird bio website
for 90 days following the conferences.

About bluebird bio, Inc.

With its lentiviral-based gene therapies, T cell immunotherapy expertise
and gene editing capabilities, bluebird bio has built a pipeline with
broad potential application in severe genetic diseases and cancer.

bluebird bio's gene therapy clinical programs include investigational
treatments for cerebral adrenoleukodystrophy, transfusion-dependent
β-thalassemia, also known as β-thalassemia major, and severe sickle cell

bluebird bio's oncology pipeline is built upon the company's lentiviral
gene delivery and T cell engineering, with a focus on developing novel T
cell-based immunotherapies, including chimeric antigen receptor (CAR T)
and T cell receptor (TCR) therapies. The company's lead oncology
programs are anti-BCMA CAR T programs partnered with Celgene.

bluebird bio's discovery research programs include utilizing
megaTAL/homing endonuclease gene editing technologies with the potential
for use across the company's pipeline.

bluebird bio has operations in Cambridge, Massachusetts; Seattle,
Washington; Durham, North Carolina and Zug, Switzerland.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the Company's product candidates and research
programs. Any forward-looking statements are based on management's
current expectations of future events and are subject to a number of
risks and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include, but
are not limited to, risks that the preliminary results from our clinical
trials will not continue or be repeated in our ongoing clinical trials,
the risk of cessation or delay of any of the ongoing or planned clinical
studies and/or our development of our product candidates, the risk of a
delay in the enrollment of patients in our clinical studies, risks that
the current or planned clinical trials of the LentiGlobin drug product
will be insufficient to support regulatory submissions or marketing
approval in the United States and European Union, the risk that our
collaborations, including the collaboration with Celgene, will not
continue or will not be successful, and the risk that any one or more of
our product candidates will not be successfully developed, approved or
commercialized. For a discussion of other risks and uncertainties, and
other important factors, any of which could cause our actual results to
differ from those contained in the forward-looking statements, see the
section entitled "Risk Factors" in our most recent Form 10-Q, as well as
discussions of potential risks, uncertainties, and other important
factors in our subsequent filings with the Securities and Exchange
Commission. All information in this press release is as of the date of
the release, and bluebird bio undertakes no duty to update this
information unless required by law.

View Comments and Join the Discussion!